Soft Tissue Sarcoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Soft Tissue Sarcoma Pipeline Insight 2024" report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Soft Tissue Sarcoma Research. Learn more about our innovative pipeline today! @ Soft Tissue Sarcoma Pipeline Outlook [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report

* July 2024:- Epizyme Inc.- A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma. The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
* July 2024:- Nationwide Children's Hospital- This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas.
* DelveInsight's Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
* The leading Soft Tissue Sarcoma Companies such as Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
* Promising Soft Tissue Sarcoma Therapies such as Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.

Stay informed about the cutting-edge advancements in Soft Tissue Sarcoma Treatments. Download for updates and be a part of the revolution in oncology care @ Soft Tissue Sarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Soft Tissue Sarcoma Emerging Drugs Profile

* AL3818: Advenchen Laboratories

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-, c-Kit, and FGFRs 1-3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells. More specifically, the mechanism involves the inhibition of the downstream ERK signaling pathway. Anlotinib has stronger anti-angiogenesis activity than that do other antiangiogenic agents (sunitinib and sorafenib). Currently, it is in Phase III stage of clinical trial evaluation to treat Soft Tissue Sarcoma.

* L19 TNF: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has previously been studied in clinical trials as monotherapy for systemic administration in patients with solid tumors and in melanoma patients using the Isolated Limb-Perfusion procedure. In preclinical models of sarcoma, Fibromun has, when combined with doxorubicin or dacarbazine (which are standard therapies for first line and third line sarcoma, respectively), cured all treated animals . Based on the encouraging results observed in the phase Ib study conducted in patients with metastatic Soft Tissue Sarcoma, three clinical trials with registration potential have started in Europe and in the United States. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Soft tissue sarcoma.

* Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types. The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase II isoform achieves the anticancer effect, while inhibiting the topoisomerase II isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase II isoform over the topoisomerase II isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.

Learn more about Soft Tissue Sarcoma Drugs opportunities in our groundbreaking Soft Tissue Sarcoma Research and development projects @ Soft Tissue Sarcoma Unmet Needs [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Soft Tissue Sarcoma Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Soft Tissue Sarcoma Pipeline Report

* Coverage- Global
* Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
* Soft Tissue Sarcoma Therapies- Retifanlimab, Gemcitabine, ADI PEG20, Ifosfamide, Chiauranib, INT230-6, Onfekafusp alfa, and others.
* Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Soft Tissue Sarcoma Pipeline on our website @ Soft Tissue Sarcoma Drugs and Companies [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Soft Tissue Sarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Anlotinib: Advenchen Laboratories, LLC
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Camsirubicin: Monopar Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* FHD-609: Foghorn Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Soft Tissue Sarcoma Key Companies
* Soft Tissue Sarcoma Key Products
* Soft Tissue Sarcoma- Unmet Needs
* Soft Tissue Sarcoma- Market Drivers and Barriers
* Soft Tissue Sarcoma- Future Perspectives and Conclusion
* Soft Tissue Sarcoma Analyst Views
* Soft Tissue Sarcoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=soft-tissue-sarcoma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.